Skip Ribbon Commands
Skip to main content

News

 

 

First results of DISCO RADIAL, a Terumo sponsored studyhttps://www.terumo-europe.com/en-emea/news/first-results-of-disco-radial-a-terumo-sponsored-studyFirst results of DISCO RADIAL, a Terumo sponsored studyLEUVEN, BELGIUM6/14/2022 10:00:00 PMLate Breaking Trial presentation at EuroPCR 2022 with simultaneous publication in the Journal of the American College of Cardiology (JACC)<p><br></p>
Holmium-166 SIRT demonstrates safety and efficacy in the treatment of Hepatocellular carcinoma (HCC)https://www.terumo-europe.com/en-emea/news/holmium-166-sirt-demonstrates-safety-and-efficacy-in-the-treatment-of-hepatocellular-carcinoma-(hcc)Holmium-166 SIRT demonstrates safety and efficacy in the treatment of Hepatocellular carcinoma (HCC)LEUVEN, BELGIUM6/13/2022 10:00:00 PM<p>​Terumo Europe N.V. is proud to share the latest clinical news regarding Holmium-166 (QuiremSpheres<sup>TM</sup> holmium-166 microspheres) Selective Internal Radiation Therapy (SIRT). On May 19, 2022, the UMC Utrecht published their latest results in the JNM 2022 from the HEPAR Primary study. The study evaluated the safety and efficacy of Holmium-166 SIRT in the treatment of HCC patients (BCLC stage B & C) without curative options. <br></p>
Terumo Appoints Three Associates as the Newest Terumo Fellowhttps://www.terumo-europe.com/en-emea/news/terumo-appoints-three-associates-as-the-newest-terumo-fellowTerumo Appoints Three Associates as the Newest Terumo FellowTOKYO, JAPAN 6/6/2022 10:00:00 PM<p>​Contributing to Terumo Group’s Core Technology in Diabetes Care, ME Devices and Neurovascular Treatment <br></p>
Radboudumc and Terumo Europe N.V. sign collaboration agreementhttps://www.terumo-europe.com/en-emea/news/radboudumc-and-terumo-europe-n-v-sign-collaboration-agreementRadboudumc and Terumo Europe N.V. sign collaboration agreementLEUVEN, BELGIUM6/1/2022 10:00:00 PM<p>​Radboudumc and Terumo Europe N.V. signed yesterday a strategic collaboration agreement. Together, the two partners will improve existing treatments for cancer patients and develop new, personalized therapies. Focus will be on the clinical use of holmium-166 microspheres, small radioactive beads.<br></p>
Terumo Pharmaceutical Solutions offers pre-fillable syringe solutions for demanding low dose applications such as ophthalmichttps://www.terumo-europe.com/en-emea/news/terumo-pharmaceutical-solutions-offers-pre-fillable-syringe-solutions-for-demanding-low-dose-applications-such-as-ophthalmiTerumo Pharmaceutical Solutions offers pre-fillable syringe solutions for demanding low dose applications such as ophthalmicLEUVEN, BELGIUM5/16/2022 10:00:00 PM<p>​Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation (TSE: 4543) and a leading manufacturer of injection, primary container, and infusion therapy devices, has launched a pre-fillable polymer syringe for low dose applications such as ophthalmic drugs.<br></p>